drugset / Trial / NCT01988909
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
Phase 2
Completed
18 enrolled
Assistance Publique - Hôpitaux de Paris
U.S. Army Medical Research and Development Command · collab
NaSingle-groupOpen-labelTreatment
Summary
The objectives of the study are to evaluate the safety and efficacy of open label treatment with WR 279,396 (topical paromomycin \& gentamicin) in patients with non-complicated, non-severe cutaneous leishmaniasis (CL).
Timeline
- Start
- 2013-09
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gentamicin | Small molecule | 0.5 % | Topical |
| Subject | Paromomycin | Small molecule | 15 % | Topical |